Neovasc Inc (TSE:NVC) (NASDAQ:NVCN) – Leerink Swann dropped their FY2017 EPS estimates for Neovasc in a report released on Wednesday. Leerink Swann analyst D. Antalffy now anticipates that the company will post earnings per share of ($0.24) for the year, down from their prior forecast of ($0.20). Leerink Swann also issued estimates for Neovasc’s Q1 2018 earnings at $0.00 EPS, Q2 2018 earnings at $0.00 EPS, Q3 2018 earnings at $0.00 EPS, Q4 2018 earnings at $0.00 EPS, FY2018 earnings at ($0.01) EPS, FY2019 earnings at $0.02 EPS and FY2020 earnings at $0.18 EPS.
TRADEMARK VIOLATION WARNING: This report was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2017/11/17/research-analysts-issue-forecasts-for-neovasc-incs-fy2017-earnings-nvc.html.
Shares of Neovasc (TSE NVC) traded up C$0.04 during mid-day trading on Friday, reaching C$1.78. 46,869 shares of the company’s stock traded hands, compared to its average volume of 111,876. Neovasc has a twelve month low of C$0.49 and a twelve month high of C$6.07.
Neovasc Inc (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company’s segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products.
Receive News & Ratings for Neovasc Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc Inc and related companies with MarketBeat.com's FREE daily email newsletter.